Ad-hoc | 29 October 2003 11:35

Stratec Biomedical Sys. english

STRATEC: EPS for first nine months almost at level of entire previous year Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STRATEC maintains its successes – ‘Earnings Per Share’ (EPS) for the first nine months are almost at the level achieved for the entire 2002 financial year Birkenfeld, October 29, 2003 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard, hereby issues a precautionary announcement of the results for the first nine months of FY 2003, pursuant to Section 15 of the German Securities Trading Law (WpHG). STRATEC increased its net profit for the first nine months of the 2003 financial year (net profit: January 1, 2003 – September 30, 2003) by 60.3% to EUR 1.069m (comparable period in 2002: EUR 0.667m). Earnings per share of EUR 0.32 as of September 30, 2003 (comparable period in 2002: EUR 0.20) therefore almost reached the level of the entire 2002 financial year (EUR 0.34); (number of underlying shares: 3,298,400). The overall performance and sales saw a clear two-digit growth. In FY 2003 the first nine months’ sales rose by 17.9% to EUR 22.739m (comparable period in 2002: EUR 19.293m). During the same period the overall performance increased by 18.7% to EUR 24.264m (comparable period in 2002: EUR 20.441m). STRATEC had 144 employees as of September 30, 2003 (September 30, 2002: 125). Key figures at a glance (IAS/IFRS): Key figures in EUR 000s 01.01.-09.30.2003 01.01.-09.30.2002 Change Sales 22,739 19,293 +17.9% Overall performance 24,264 20,441 +18.7% EBITDA 2,602 1,841 +41.3% EBIT 1,946 1,231 +58.1% EBT 1,746 1,074 +62.6% Net income for the period 1,069 667 +60.3% end of ad-hoc-announcement (c)DGAP 29.10.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: The company would like to draw attention to the fact that the first and third quarters of a given financial year have historically generated lower earnings than the respective second and fourth quarters. Due to the prevailing insignificant material relevance of STRATEC NewGen GmbH during the start-up stage STRATEC Biomedical Systems AG will continue to present a non-consolidated financial statement. The operating loss of STRATEC NewGen GmbH is cumulatively processed in the ‘Other Operating Expenses’ and in the ‘Other Accruals’ of the parent company. STRATEC NewGen GmbH is a wholly-owned subsidiary of STRATEC Biomedical Systems AG. About STRATEC Biomedical Systems AG: STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. STRATEC is a publicly listed stock corporation. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges. The detailed interim report will be dispatched to our investors on November 12, 2003 and can be downloaded from the company’s homepage from around 3 p.m. on the same day. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Tel: +49 (0) 70 82 / 79 16 43 Fax: +49 (0) 70 82 / 79 16 999 E-mail: ir@stratec-biomedical.de ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 291135 Okt 03